{"doi":"10.1016/j.anai.2019.08.293","title":"P227 ASTHMA EXACERBATION REDUCTION IN ADULTS WITH HIGH/LOW AIRWAY REVERSIBILITY FOLLOWING OMALIZUMAB TREATMENT: RESULTS FROM PROSPERO","abstract":null,"journal":"Annals of Allergy, Asthma & Immunology","year":2019,"id":679803,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1776205,"name":"F. Barsanti","orcid":null,"position":1,"is_corresponding":false},{"id":1776206,"name":"T. Haselkorn","orcid":null,"position":2,"is_corresponding":false},{"id":1776208,"name":"B. Yoo","orcid":null,"position":3,"is_corresponding":false},{"id":1776211,"name":"B. Creasy","orcid":null,"position":4,"is_corresponding":false},{"id":1776213,"name":"M. Wechsler","orcid":null,"position":5,"is_corresponding":false},{"id":1776204,"name":"S. DeLeon","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"P227 ASTHMA EXACERBATION REDUCTION IN ADULTS WITH HIGH/LOW AIRWAY REVERSIBILITY FOLLOWING OMALIZUMAB TREATMENT: RESULTS FROM PROSPERO","abstract":null,"is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W2983055706","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1081120619308828?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1081120619308828?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.anai.2019.08.293","host_type":"journal"}],"fields_of_study":["Asthma and respiratory diseases"],"mesh_terms":[],"keywords":["Omalizumab","Exacerbation","Medicine","Asthma exacerbations","Airway","Asthma","Lung function","Intensive care medicine","Lung","Internal medicine","Immunology","Anesthesia","Immunoglobulin E","Antibody"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T13:49:50.438610Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}